CanSino Biologics (688185.SH) Secures NMPA Approval for Recombinant Trivalent Poliomyelitis Vaccine Clinical Trials

Stock News

2025/07/16

CanSino Biologics (688185.SH) announced it has obtained clinical trial approval from China's National Medical Products Administration (NMPA) for its recombinant trivalent poliomyelitis vaccine (Sf-RVN cell). The regulatory clearance permits the company to initiate clinical studies evaluating the vaccine's efficacy in preventing poliomyelitis caused by type I, II, and III poliovirus infections. This milestone advances the company's innovative vaccine pipeline targeting preventable diseases with significant public health impact.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1101741306"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1101741306\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1101741306?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-16 16:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101741306","market":"hk","top_or_hot":-1,"title":"CanSino Biologics (688185.SH) Secures NMPA Approval for Recombinant Trivalent Poliomyelitis Vaccine Clinical Trials","media":"Stock News","content":"<p>CanSino Biologics (688185.SH) announced it has obtained clinical trial approval from China's National Medical Products Administration (NMPA) for its recombinant trivalent poliomyelitis vaccine (Sf-RVN cell). The regulatory clearance permits the company to initiate clinical studies evaluating the vaccine's efficacy in preventing poliomyelitis caused by type I, II, and III poliovirus infections. This milestone advances the company's innovative vaccine pipeline targeting preventable diseases with significant public health impact.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CanSino Biologics (688185.SH) Secures NMPA Approval for Recombinant Trivalent Poliomyelitis Vaccine Clinical Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCanSino Biologics (688185.SH) Secures NMPA Approval for Recombinant Trivalent Poliomyelitis Vaccine Clinical Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-07-16 16:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CanSino Biologics (688185.SH) announced it has obtained clinical trial approval from China's National Medical Products Administration (NMPA) for its recombinant trivalent poliomyelitis vaccine (Sf-RVN cell). The regulatory clearance permits the company to initiate clinical studies evaluating the vaccine's efficacy in preventing poliomyelitis caused by type I, II, and III poliovirus infections. This milestone advances the company's innovative vaccine pipeline targeting preventable diseases with significant public health impact.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688185","symbol_name":"康希诺","start_time":0,"source_url":"","article_id":"1101741306","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101741306","pubTimestamp":1752655645,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CanSino Biologics (688185.SH) announced it has obtained clinical trial approval from China's National Medical Products Administration (NMPA) for its recombinant trivalent poliomyelitis vaccine...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159646":"疫苗","688185":"康希诺","BK0239":"医药制造","BK1576":"医药外包概念","03347":"泰格医药","BK1141":"生命科学工具和服务","BK1583":"高瓴概念"},"translate_title":"康希诺生物（688185.SH）重组三价脊髓灰质炎疫苗临床试验获NMPA批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159646":1,"688185":1,"03347":1},"content_text":"CanSino Biologics (688185.SH) announced it has obtained clinical trial approval from China's National Medical Products Administration (NMPA) for its recombinant trivalent poliomyelitis vaccine (Sf-RVN cell). The regulatory clearance permits the company to initiate clinical studies evaluating the vaccine's efficacy in preventing poliomyelitis caused by type I, II, and III poliovirus infections. This milestone advances the company's innovative vaccine pipeline targeting preventable diseases with significant public health impact.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}